New AMA policies focus on GLP-1 coverage, resisting corporate medicine

The American Medical Association (AMA) has adopted new policies aimed at increasing access to obesity care drugs, reducing the corporatisation of healthcare and urging flexibility in the treatment of opioid use disorder. Key policies include advocating health insurance coverage for obesity treatment drugs, resisting corporate encroachment into medical practices, and calling for the elimination of buprenorphine treatment dose limits for patients with opioid use disorder.